Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
3.680
-0.410 (-10.02%)
At close: May 13, 2026, 4:00 PM EDT
3.750
+0.070 (1.90%)
After-hours: May 13, 2026, 5:34 PM EDT
Ironwood Pharmaceuticals Revenue
Ironwood Pharmaceuticals had revenue of $106.51M in the quarter ending March 31, 2026, with 158.87% growth. This brings the company's revenue in the last twelve months to $361.51M, up 13.80% year-over-year. In the year 2025, Ironwood Pharmaceuticals had annual revenue of $296.15M, down -15.72%.
Revenue (ttm)
$361.51M
Revenue Growth
+13.80%
P/S Ratio
1.68
Revenue / Employee
$3,615,140
Employees
100
Market Cap
605.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 296.15M | -55.26M | -15.72% |
| Dec 31, 2024 | 351.41M | -91.33M | -20.63% |
| Dec 31, 2023 | 442.74M | 32.14M | 7.83% |
| Dec 31, 2022 | 410.60M | -3.16M | -0.76% |
| Dec 31, 2021 | 413.75M | 24.23M | 6.22% |
| Dec 31, 2020 | 389.52M | -38.89M | -9.08% |
| Dec 31, 2019 | 428.41M | 81.77M | 23.59% |
| Dec 31, 2018 | 346.64M | 48.36M | 16.21% |
| Dec 31, 2017 | 298.28M | 24.32M | 8.88% |
| Dec 31, 2016 | 273.96M | 124.40M | 83.18% |
| Dec 31, 2015 | 149.56M | 73.12M | 95.66% |
| Dec 31, 2014 | 76.44M | 53.56M | 234.06% |
| Dec 31, 2013 | 22.88M | -127.36M | -84.77% |
| Dec 31, 2012 | 150.25M | 84.37M | 128.09% |
| Dec 31, 2011 | 65.87M | 22.01M | 50.19% |
| Dec 31, 2010 | 43.86M | 9.54M | 27.78% |
| Dec 31, 2009 | 34.32M | 15.94M | 86.70% |
| Dec 31, 2008 | 18.38M | 7.92M | 75.68% |
| Dec 31, 2007 | 10.46M | 7.32M | 233.25% |
| Dec 31, 2006 | 3.14M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 858.28M |
| Pacira BioSciences | 734.86M |
| Amphastar Pharmaceuticals | 720.53M |
| Emergent BioSolutions | 676.80M |
| Esperion Therapeutics | 418.24M |
| Xeris Biopharma Holdings | 314.85M |
| Kamada | 180.46M |
| Cronos Group | 159.54M |
IRWD News
- 6 days ago - Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 6 days ago - Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance - Business Wire
- 9 days ago - Ironwood presents new findings at DDW 2026 from survey treatment of SBS - TheFly
- 9 days ago - Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS) - Business Wire
- 13 days ago - Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call - Business Wire
- 20 days ago - Ironwood to present data from Landmark survey on SBS - TheFly
- 20 days ago - Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026 - Business Wire
- 2 months ago - Ironwood Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026 - Transcripts